PLoS ONE (Jan 2018)
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.
- Mark Merchant,
- John Moffat,
- Gabriele Schaefer,
- Jocelyn Chan,
- Xi Wang,
- Christine Orr,
- Jason Cheng,
- Thomas Hunsaker,
- Lily Shao,
- Stephanie J Wang,
- Marie-Claire Wagle,
- Eva Lin,
- Peter M Haverty,
- Sheerin Shahidi-Latham,
- Hai Ngu,
- Margaret Solon,
- Jeffrey Eastham-Anderson,
- Hartmut Koeppen,
- Shih-Min A Huang,
- Jacob Schwarz,
- Marcia Belvin,
- Daniel Kirouac,
- Melissa R Junttila
Affiliations
- Mark Merchant
- John Moffat
- Gabriele Schaefer
- Jocelyn Chan
- Xi Wang
- Christine Orr
- Jason Cheng
- Thomas Hunsaker
- Lily Shao
- Stephanie J Wang
- Marie-Claire Wagle
- Eva Lin
- Peter M Haverty
- Sheerin Shahidi-Latham
- Hai Ngu
- Margaret Solon
- Jeffrey Eastham-Anderson
- Hartmut Koeppen
- Shih-Min A Huang
- Jacob Schwarz
- Marcia Belvin
- Daniel Kirouac
- Melissa R Junttila
- DOI
- https://doi.org/10.1371/journal.pone.0192059
- Journal volume & issue
-
Vol. 13,
no. 1
p. e0192059
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0185862.].
